Serial CTRS (CT Response Score) improves prediction of overall survival compared to RECIST 1.1 and Tumor Volume Change in advanced NSCLC CHICAGO--(BUSINESS WIRE)--Onc.AI, a digital health company ...

The hematology/oncology workforce endorses the incorporation of AI into medical education, according to findings presented at ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

A new phase: Since before he became secretary, Kennedy has talked about using AI in myriad ways, including to provide ...

BeOne Medicines Ltd. (NASDAQ:ONC) has unveiled new data from the pivotal Phase 3 SEQUOIA trial at the 2025 ASCO Annual ...

While we acknowledge the potential of ONC as an investment, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame.